Galapagos expands and extends drug discovery collaboration with Amgen into 2008
Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive an upfront fee of $2.4 million as a payment for 2007 research costs. Additionally, Galapagos may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses.
The initial collaboration, announced in January 2003, involves the identification of lead candidates against multiple ion channel targets. The new agreement expands this collaboration to include all classes of targets, including ion channel, GPCR and kinase targets. Additionally, the agreement has been expanded to include the supply of BioFocus DPI's compound collection comprising 700,000 synthetic small molecules and its proprietary natural product compound collection containing 145,000 pre-purified subfractions, pure natural products, and semi-synthetic natural products.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Filming chemistry with a high speed x-ray camera - Chemistry happens all around us. A chemical reaction is a rearrangement of atoms in and between molecules, the breaking of old and the formation of new bonds. The glue that binds atoms in molecules an
Kinaxo Starts Collaboration with Roche in the Field of Phosphoproteomics
Sticking sugar to protein - Researchers clarified the 3D structure of an important enzyme that links sugar to proteins – a breakthrough
Cancer control: Structure of important transport protein solved - Discovery of promising binding site
How solid-state batteries degrade - What happens during operation?
Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System
Closing in on mystery surrounding dangerous blood syndromes - Genetically driven MDS enabled by gene linked to metabolism and oxygen in cells
Long-COVID - all a question of genes? - New study results show possible risk factor
Beckman Coulter and Fujirebio enter into partnership - The goal is a patient-friendly, blood-based Alzheimer's disease test
Beta cells from stem cells: Potential for cell replacement therapy - Quality control with CD177 can help save lots of time, efforts and money
Clinical Reference Laboratory Inc to build European laboratory hub in UK
